oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer
School of Medical Sciences, Örebro University, Örebro, Sweden.
Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; Faculty of Allied Health Sciences, Chettinad Academy of Research and Education, Kelambakkam, India.
Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Örebro University, School of Medical Sciences.
2018 (English)In: Journal of Cancer, ISSN 1837-9664, E-ISSN 1837-9664, Vol. 9, no 11, p. 2046-2053Article in journal (Refereed) Published
Abstract [en]

Colorectal cancer is a commonly diagnosed malignancy and also the major cause of death worldwide. Chemotherapy is the primary therapy for advanced colorectal cancer. Although oxaliplatin has potential effect in colorectal cancer therapy, the molecular mechanisms involved in its cytotoxic effects are not well elucidated. This study outlines the regulatory effects of oxaliplatin on miRNAs expression in colon cancer cells and correlates it with the changing microRNA expression with p53 and p73 expression status in cells. HCT116(p53+/+) and HCT116(p53-/-) cells were exposed to oxaliplatin, and the cellular viability was determined by XTT. p73 was knocked down using siRNA and the tumor cells were then treated with oxaliplatin. The expression profile of 384 miRNAs was determined by TaqMan (R) human miRNA array and calculated by the Delta Delta C-t method. Cellular viability was found to decrease after the treatment with oxaliplatin in a dose-dependent manner. The wild-type p53 cells were found to be more sensitive than the null-p53 derivatives. A selective set of miRNAs were either up-regulated or down-regulated in response to the oxaliplatin treatment with a presumable role of p53 and p73 proteins. The miRNAs expression is known to influence the pharmacodynamic mechanisms of oxaliplatin and these effects have been observed to be regulated by p53 and p73. Our results may therefore provide more evidence for identifying a suitable biomarker for the diagnosis of colon cancer.

Place, publisher, year, edition, pages
Ivyspring International Publisher , 2018. Vol. 9, no 11, p. 2046-2053
Keywords [en]
Oxaliplatin, miRNAs, p53, p73, colon cancer cells
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-67344DOI: 10.7150/jca.24474ISI: 000434287700019PubMedID: 29896290Scopus ID: 2-s2.0-85048336277OAI: oai:DiVA.org:oru-67344DiVA, id: diva2:1221547
Funder
Swedish Cancer SocietySwedish Research Council
Note

Funding Agency:

Health Research Council in the South-East of Sweden

Available from: 2018-06-20 Created: 2018-06-20 Last updated: 2018-06-20Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Zhang, Hong

Search in DiVA

By author/editor
Zhang, Hong
By organisation
School of Medical Sciences
In the same journal
Journal of Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 2205 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf